Mega Genomics Ltd. reported its unaudited interim results for the six months ended 30 June 2025. Revenue for the period was CNY 81.28 million, reflecting a decrease of 24.2%. Revenue from consumer genetic testing services and ancillary services amounted to CNY 75.95 million, down 27.3%. The company’s income tax expense for the half year was CNY 5.43 million, with an additional deferred tax expense of CNY 0.45 million. According to the company, the year-on-year decrease in revenue and net profit was primarily due to an adjustment in sales strategy, leading to a temporary decline in revenue while certain costs remained relatively fixed. As of 30 June 2025, Mega Genomics Ltd. had performed over 24 million genetic tests in total and maintained coverage of healthcare institutions in more than 340 cities across China. The company continues to expand its presence through cooperation with e-commerce and online healthcare platforms, enhancing its sales and marketing network.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mega Genomics Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260204-12014874), on February 04, 2026, and is solely responsible for the information contained therein.